JP2023528206A5 - - Google Patents

Info

Publication number
JP2023528206A5
JP2023528206A5 JP2022568691A JP2022568691A JP2023528206A5 JP 2023528206 A5 JP2023528206 A5 JP 2023528206A5 JP 2022568691 A JP2022568691 A JP 2022568691A JP 2022568691 A JP2022568691 A JP 2022568691A JP 2023528206 A5 JP2023528206 A5 JP 2023528206A5
Authority
JP
Japan
Prior art keywords
cancer
seq
modified immune
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2021/051157 external-priority patent/WO2021229234A1/en
Publication of JP2023528206A publication Critical patent/JP2023528206A/ja
Publication of JP2023528206A5 publication Critical patent/JP2023528206A5/ja
Pending legal-status Critical Current

Links

JP2022568691A 2020-05-13 2021-05-13 癌または腫瘍の治療方法 Pending JP2023528206A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063024077P 2020-05-13 2020-05-13
US63/024,077 2020-05-13
US202063030503P 2020-05-27 2020-05-27
US63/030,503 2020-05-27
US202063089611P 2020-10-09 2020-10-09
US63/089,611 2020-10-09
PCT/GB2021/051157 WO2021229234A1 (en) 2020-05-13 2021-05-13 Method of treatment of cancer or tumour

Publications (2)

Publication Number Publication Date
JP2023528206A JP2023528206A (ja) 2023-07-04
JP2023528206A5 true JP2023528206A5 (https=) 2025-03-28

Family

ID=76098970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568691A Pending JP2023528206A (ja) 2020-05-13 2021-05-13 癌または腫瘍の治療方法

Country Status (7)

Country Link
US (1) US20230190803A1 (https=)
EP (1) EP4149493A1 (https=)
JP (1) JP2023528206A (https=)
CN (1) CN116264826A (https=)
AU (1) AU2021272400A1 (https=)
CA (1) CA3178582A1 (https=)
WO (1) WO2021229234A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021144338A1 (en) * 2020-01-14 2021-07-22 Adaptimmune Limited Method of treatment of cancer or tumour
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
GB202213051D0 (en) * 2022-09-07 2022-10-19 Adaptimmune Ltd Method of treatment of head and neck cancer
GB202213052D0 (en) * 2022-09-07 2022-10-19 Adaptimmune Ltd Method and treatment of bladder cancer
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102719401B (zh) * 2012-07-05 2014-04-23 时宏珍 Hla-a0201限制性抗mage抗原特异性ctl的制备方法
WO2017079746A2 (en) * 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
KR20190059874A (ko) * 2016-04-08 2019-05-31 어댑티뮨 리미티드 T 세포 수용체
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
WO2021144338A1 (en) * 2020-01-14 2021-07-22 Adaptimmune Limited Method of treatment of cancer or tumour

Similar Documents

Publication Publication Date Title
JP2023528206A5 (https=)
JP2023526259A5 (https=)
Kishore et al. Current advancements and future perspectives of immunotherapy in colorectal cancer research
Mathew et al. Combining chemotherapy with PD-1 blockade in NSCLC
Duffy et al. Immunological off-target effects of standard treatments in gastrointestinal cancers
TW201545759A (zh) 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體
Aguiar Jr et al. Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
Rivera Vargas et al. Can immunogenic chemotherapies relieve cancer cell resistance to immune checkpoint inhibitors?
US20230190802A1 (en) Method of treatment of cancer or tumour
CN107801379A (zh) 抗癌剂
BR112016024972B1 (pt) Anticorpo monoclonal humanizado, polinucleotídeo isolado,plasmídeo, composições farmacêutica e de disgnóstico, usos do dito anticorpo monoclonal humanizado e método in vitro para determinar a expressão de ceacam1
AU2026201847A1 (en) Methods, therapies and uses for treating cancer
US10980859B2 (en) In vivo individualized systemic immunotherapeutic method and device
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
Miljkovic et al. Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
Sarkisian et al. Current clinical trials in the treatment of advanced melanomas
Terlecka et al. LAG-3 as a therapeutic target in melanoma
CN119486753A (zh) 个体化癌症表位及其使用方法
US20230181633A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
EP4240406A1 (en) Assessment of cancers for treatment with a cd33/cd3 bispecific t cell engager
WO2022046833A1 (en) Methods of treating cancer by administering a pd-1 inhibitor
JP2023513350A5 (https=)
CA2464947C (en) Combination therapy for treating disease
US20240016844A1 (en) Methods of treatment using a genetically modified autologous t cell immunotherapy
JP2025530188A (ja) 膀胱がんの治療において使用するための改変ｔ細胞